{
    "clinical_study": {
        "@rank": "67327", 
        "arm_group": {
            "arm_group_label": "leuprorelin acetate", 
            "description": "Subcutaneous administration of leuprorelin acetate once every 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this survey is to examine the safety and efficacy of long-term use (96 weeks)\n      of leuprorelin acetate SR (slow release) 11.25 mg for injection (Leuplin SR 11.25 mg for\n      Injection) in premenopausal breast cancer patients in daily medical practice, as well as to\n      examine factors that can influence the safety and efficacy of treatment with leuprorelin\n      acetate SR 11.25 mg for injection (Leuplin SR 11.25 mg for Injection)."
        }, 
        "brief_title": "Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey \"Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)\"", 
        "completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This survey was designed to examine the safety and efficacy of long-term use (96 weeks) of\n      leuprorelin acetate 3 months depot for injection (Leuplin SR 11.25 mg for Injection) in\n      premenopausal breast cancer patients in daily medical practice, as well as to examine\n      factors that can influence the safety and efficacy of treatment with leuprorelin acetate SR\n      11.25 mg for injection (Leuplin SR 11.25 mg for Injection).\n\n      For adults, 11.25 mg of leuprorelin acetate is usually administered subcutaneously once\n      every 12 weeks. Prior to injection, the plunger rod of the syringe is pushed upward with the\n      needle pointed upward, allowing the entire suspension fluid contained to be transferred to\n      the powder. The powder is then fully suspended in the fluid while ensuring that bubbles are\n      not generated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Premenopausal breast cancer patients (patients with advanced or recurrent breast\n             cancer and patients who received adjuvant therapy).\n\n        Exclusion Criteria:\n\n          -  Patients with a history of treatment with Leuplin SR 11.25 mg for Injection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Breast cancer"
            }
        }, 
        "enrollment": {
            "#text": "651", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154139", 
            "org_study_id": "265-201"
        }, 
        "intervention": {
            "arm_group_label": "leuprorelin acetate", 
            "description": "Leuprorelin acetate SR 11.25 mg for injection", 
            "intervention_name": "Leuprorelin acetate", 
            "intervention_type": "Drug", 
            "other_name": "Leuplin SR 11.25 mg for Injection"
        }, 
        "intervention_browse": {
            "mesh_term": "Leuprolide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "May 29, 2014", 
        "number_of_groups": "1", 
        "official_title": "Leuplin SR 11.25 mg for Injection Specified Drug-use Survey \"Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of leuprorelin acetate whether or not it was considered related to treatment. Among these, events that are considered as having a causal relationship with leuprorelin acetate are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "For 96 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154139"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "For patients with advanced or recurrent breast cancer, the antitumor efficacy (best response) of leuprorelin acetate SR 11.25 mg for injection (Leuplin SR 11.25 mg for Injection) will be evaluated.", 
                "measure": "Antitumor efficacy over the 96-week period of treatment with leuprorelin acetate SR 11.25 mg for injection (Leuplin SR 11.25 mg for Injection) in patients with advanced or recurrent breast cancer", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 96 weeks of treatment"
            }, 
            {
                "description": "For patients who were treated as adjuvant therapy, recurrence-free survival will be determined and tabulated, based on the date recurrence is confirmed, the presence or absence of recurrence, continued survival or death, and the date of death.", 
                "measure": "Recurrence-free survival over the 96-week period of treatment with leuprorelin acetate SR 11.25 mg for injection (Leuplin SR 11.25 mg for Injection) in patients who were treated asadjuvant therapy", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 96 weeks of treatment"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2005", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}